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Since targeted downregulation of MLL-AF9 induces strong cell-growth inhibition and apoptosis, 5, 6 our results indicate that HDACi by VPA can overcome the resistance conferred by MLL-AF9 in MLL-AF9 AML-M5 cells, even in the presence of an increased expression of MLL-AF9.
p21 and CG2 emerged as the main cell-cycle inhibitory genes upregulated by VPA in MLL-AF9 AML. CG2 induction is p53-independent. 3 Induction of p21 by VPA was also p53-independent as THP-1 is p53-absent. 7 As in AML with MLL fusion proteins (including MLL-AF9) p53 is functionally inactivated leading to a lost response to DNA damage, 8 our data indicate that VPA could activate a p53-independent G1 cell-cycle arrest and apoptosis in MLL-mut AML.
Finally, we demonstrated not only that p21 can be used as a tumor-specific marker of VPA treatment in MLLmut AML but that it also plays an active and key role in G1 cell-cycle arrest in AML-M5 expressing MLL-AF9. By contrast, the VPA-induced CG2 is not tumor-specific and has no relevant role in G1 cellcycle arrest. Children with acute myeloid leukemia (AML) in Italy have a probability of event-free survival of 53% at 5 years. 1 Acute myeloid leukemia associated with rearrangements involving the MLL gene (translocations, duplications, inversions, deletions) are frequently found in infants and in patients with secondary leukemias following treatment with DNA topoisomerase-II inhibitors, and are most often associated with the AML-M5 or -M4 FAB subtypes. 2 The MLL gene (also called ALL-1 or HRX), located at 11q23, is involved in over 60 different translocations leading to gene fusion and over 30 partner genes have so far been cloned and partially characterized. 2 The most common translocation is the t(9;11)(p22;q23) giving rise to the MLL-AF9 fusion gene, while other recurring translocations are the t(11;19)(q23;p13.3) and the t(11;19)(q23;p13.1), producing, respectively, the MLL-ENL and MLL-ELL oncogenes. Several studies have demonstrated that the transcriptional effector functions of the MLL fusion partners are essential for leukemogenesis; however, there are few common characteristics among these partner proteins that can clarify their role in leukemogenesis.
We report the identification of ArgBP2 (Arg-binding-protein-2) as a new partner gene of MLL in a case of infant AML. A 3-monthold girl was diagnosed as having AML-M5. Her peripheral blood mononuclear cell count was 131 Â 10 6 /ml. Peripheral blood and bone marrow smears showed 16 and 30% of blasts, respectively. Immunophenotypic analysis revealed that the leukemic blasts were highly positive (from 42 to 77%) for CD14, CD15, CD33 and C11b.In consideration to the high incidence of MLL gene rearrangements in patients with AML-M5, FISH analysis with MLL-specific probes was performed: the results showed separate green and orange signals in a MLL allele in 25% of the interphases analyzed, indicating the presence of a translocation involving MLL (Figure 1b) .
Original panhandle polymerase chain reaction (PCR) was performed to identify the MLL partner gene at the genomic level. 3 Sequencing of the 4250 bp original panhandle PCR 
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Letters to the Editor product ( Figure 2a ) revealed a breakpoint junction between MLL intron 7 (nucleotide 3214, Genbank accession no. X83604), and ArgBP2 intron 18 (nucleotide 18941634, GenBank Accession number NT_022792). In order to identify the chimeric transcript, cDNA panhandle PCR has been performed, 4 revealing fusion transcript of MLL exon 7 to ArgBP2 exon 19 (Figure 2b ). This fusion transcript maintained the open reading frame of both genes (Figure 2d ). To verify that this fusion product was specifically expressed in the leukemic cells, we performed reverse transcription-polymerase chain reaction (RT-PCR) analyses using gene specific primers. We detected an MLL-ArgBP2 fusion transcript product of the expected size (341 bp), only in the patient's leukemic cells (Figure 2c ), while the reciprocal ArgBP2-MLL fusion transcript was not detected (data not shown). The wild-type ArgBP2 allele was not expressed either in leukemic cells from the patient or in a normal bone marrow sample (Figure 2c) .
Immunofluorescence analysis showed that MLL-ArgBP2 localizes to the nucleus with a punctate localization pattern characteristic of the MLL chimeric proteins ( Figure 3A) . 2 In order to study the potential oncogenic effect of MLLArgBP2, murine bone marrow cells were transduced with a Figure 2 Identification of the MLL-Arg-binding-protein-2 (ArgBP2) genomic breakpoint, fusion chimeric transcript and structure of the putative fusion protein. (a) Original panhandle polymerase chain reaction (PCR) 3 : H, HindIII marker; lanes 1 and 2, two independent reactions yielded a 4.2 kb PCR product. (b) cDNA panhandle PCR analysis 4 of diagnostic marrow: M, a 100-bp size marker (Invitrogen, Carlsbad, USA); as expected, a smear of several fusion transcripts (lane 1) was found. The DNA and cDNA Panhandle PCR products were subcloned into Max Efficiency Cells (Invitrogen, Carlsbad, USA) using recombination PCR strategies. 4 Selected clones were sequenced using the M13 vector specific primers and the BigDye chain-terminator method was used with an ABI-377 DNA sequencer (Applied Biosystems, Foster City, USA). A database search was carried out using the BLASTN algorithm on the NIH Blast server. (c) To confirm the cDNA panhandle PCR findings of MLL-ArgBP2 transcript, and to evaluate the expression of ArgBP2-MLL and ArgBP2 mRNAs, conventional reverse transcription-polymerase chain reactions (RT-PCRs; Supplementary Information) were performed using the following newly designed primers: for MLL-ArgBP2, MLL-sense-exon-7 ( 5 and confirmed by sequencing. For this purpose, the ENL portion of an MSCVneoMLL-ENL plasmid that was originally used in the CFC assay 5 was replaced by ArgBP2. MLL-ENL and the truncated MLL portion (MLL-no fusion) without a fusion partner served as positive and negative controls, respectively. The CFC assay was performed twice in triplicates as previously described. 5 Results after three rounds of replating. (c) The appropriate MLL-ArgBP2 expression was verified by immunodetection in extracts of the retroviral packaging cell line. Proteins transiently expressed were subjected to Western blot analysis using mouse monoclonal anti-FLAG antibody (Sigma). Lane 1, MLL-ArgBP2 (160 kDa); lane 2, MLL-no fusion (152 kDa).
Letters to the Editor retroviral construct expressing the MLL-ArgBP2 protein. Similar constructs coding for either an MLL-ENL fusion or a truncated MLL without fusion partner served as controls. The growth properties of the transduced cells were evaluated in a methylcellulose serial replating assay. 5 In the first round of plating, approximately equal numbers of colonies were observed for cells transduced with MLL-ENL, MLL-ArgBP2, and MLL without fusion partner, demonstrating a comparable rate of transduction efficiency in all three retroviruses ( Figure 3B ). Despite the successful transduction of all three samples only MLL-ENL expressing cells demonstrated transformation and maintained replicative potential after two rounds of replating ( Figure 3B ). In contrast, MLL-ArgBP2 transduced cells failed to form colonies under these particular assay conditions ( Figure 3B ). This result is in agreement with four other proteins (GRAF, FBP17, ABI-1 and LASP1) that have been characterized in which MLL is fused to a cytoplasmic partner. 5 We have shown that the ArgBP2 gene, mapping to chromosome band 4q35, is a new partner gene of MLL in a case of infant AML-M5. Arg-binding-protein-2 is a member of a recently described adaptor protein family comprising Vinexin and CAP (CBL associated proteins)/ponsin, involved in the regulation of actin cytoskeleton organization and signal transduction, whose members are characterized by a Sorbin Homology (SoHo) domain and three Src homology 3 (SH3-A, -B and -C) domains (Figure 2e) . 6 The SoHo region may play an important role in targeting ArgBP2 to the cell surface, while the SH3 domains interact with the proline-rich motifs of the binding proteins and may coordinate actin function, signaling, and membrane trafficking. 6 The most C-terminal SH3 domain (SH3-C) of ArgBP2 is retained in the predicted MLL-ArgBP2 fusion protein (Figure 2e ). Seven other MLL-partner genes can also encode the SH3 domain-containing protein: namely, EEN, ABI-1, LASP1, GRAF, FBP17, AF3p21 and MYO1F. The SH3 domain is retained in the MLL fusion proteins involving EEN, ABI-1, LASP1, GRAF, FBP17 and MYO1F (where SH3 is located at the C-terminus), but not in the case of AF3p21 (N-terminal location).
The binding proteins identified so far interacting with ArgBP2 through the SH3-C domain (retained in MLL-ArgBP2) include: ABL, Arg and CBL 7 ; synaptojanin and dynamin 6 ; PAK1. 8 These ArgBP2 binding proteins are involved in the regulation of the actin cytoskeleton, cell motility and shape, cell proliferation and survival.
In ArgBP2, the SH3-A, -B and -C domains ( Figure 2c ) interact with the proline-rich motifs of the nonreceptor tyrosine kinase ABL and Arg (SH3-A and -C) and/or of the proto-oncogene ubiquitin ligase CBL (SH3-B and -C). 7 CBL, which specifically targets activated protein tyrosine kinases and regulates their signaling, is a negative regulator of the activated ABL by mediating its ubiquitin-dependent degradation in the proteasome. 7 Binding of CBL to ABL depends on the presence of the adaptor protein, ArgBP2: phosphorylation of CBL and ArgBP2 by activated ABL kinases stabilizes the complex, thereby facilitating CBL-induced ubiquitination and the subsequent degradation of ABL and ArgBP2. 7 Interestingly, also CBL has been found to be a MLL fusion partner in a patient with de novo AML. 2 
